Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy

Antioxidants and Redox Signaling

Volumn 15, Issue 5, 2011, Pages 1167-1178

  Carrano, Anna ^a   Hoozemans, Jeroen J M ^a   Van Der Vies, Saskia M ^a   Rozemuller, Annemieke J M ^a   Van Horssen, Jack ^a   De Vries, Helga E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALLOPURINOL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CLAUDIN 5; DIPHENYLIODONIUM SALT; OCCLUDIN; PROTEIN ZO1; REACTIVE OXYGEN METABOLITE; RECEPTOR; RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; THIOCTIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CAPILLARY CEREBRAL AMYLOID ANGIOPATHY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROGLIA; MOLECULAR MECHANICS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIGHT JUNCTION; UPREGULATION; VASCULAR AMYLOIDOSIS;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANTIGENS, NEOPLASM; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; CAPILLARIES; CELL LINE; CEREBRAL AMYLOID ANGIOPATHY; DOWN-REGULATION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHOPROTEINS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; TIGHT JUNCTIONS;

EID: 79960793961     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.3895     Document Type: Article

References (50)

1. Akiyama H, Ikeda K, Kondo H, and McGeer PL. Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci Lett 146: 152-154, 1992.
2. Attems J. Sporadic cerebral amyloid angiopathy: Pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110: 345-359, 2005. (Pubitemid 41672180)
3. Attems J, Jellinger KA, and Lintner F. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 110: 222-231, 2005. (Pubitemid 41430650)
4. Babior BM. The NADPH oxidase of endothelial cells. IUBMB Life 50: 267-269, 2000. (Pubitemid 32289084)
5. Balcells M, Wallins JS, and Edelman ER. Amyloid beta toxicity dependent upon endothelial cell state. Neurosci Lett 441: 319-322, 2008.
6. Blanc EM, Toborek M, Mark RJ, Hennig B, and Mattson MP. Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem 68: 1870-1881, 1997. (Pubitemid 27176122)
7. Blasig IE, Bellmann C, Cording J, del Vecchio G, Zwanziger D, Huber O, and Haseloff RF. Occludin protein family: oxidative stress and reducing conditions. Antioxid Redox Signal 15: 1195-1219, 2011.
8. Braak H and Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82: 239-259, 1991.
9. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 91: 6-14, 1996.
10. Coisne C and Engelhardt B. Tight junctions in brain barriers during CNS inflammation. Antioxid Redox Signal 15: 1285-1303, 2011.
11. Deane R and Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4: 191-197, 2007. (Pubitemid 46562394)
12. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, and Stopa EG. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112: 405-415, 2006. (Pubitemid 44469161)
13. Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, and Fine RE. Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of dutch-type mutant. J Neurosci Res 60: 804-810, 2000. (Pubitemid 30399552)
14. Farkas E and Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64: 575-611, 2001. (Pubitemid 32304447)
15. González-Mariscal L, Quiró s M, and Díaz- Coránguez M. ZO proteins and redox-dependent processes. Antioxid Redox Signal 15: 1235-1253, 2011.
16. Gonzalez-Velasquez FJ, Kotarek JA, and Moss MA. Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem 107: 466-477, 2008.
17. Hawkins BT and Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57: 173-185, 2005. (Pubitemid 41043883)
18. Higuchi Y, Miyakawa T, Shimoji A, and Katsuragi S. Ultrastructural changes of blood vessels in the cerebral cortex in Alzheimer's disease. Jpn J Psychiatry Neurol 41: 283-290, 1987. (Pubitemid 17121818)
19. Hsu MJ, Sheu JR, Lin CH, Shen MY, and Hsu CY. Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration. Biochim Biophys Acta 1800: 290-206, 2010.
20. Jeynes B and Provias J. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: A regional comparison. Acta Neuropathol 112: 417-427, 2006. (Pubitemid 44469162)
21. Kalaria RN. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev 4: 226-260, 1992.
22. Lehner C, Gehwolf R, Tempfer H, Krizbai I, Hennig B, Bauer HC, and Bauer H. Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid Redox Signal 15: 1305-1323, 2011.
23. Li G, Ma R, Huang C, Tang Q, Fu Q, Liu H, Hu B, and Xiang J. Protective effect of erythropoietin on beta-amyloidinduced PC12 cell death through antioxidant mechanisms. Neurosci Lett 442: 143-147, 2008.
24. Li JM and Shah AM. ROS generation by nonphagocytic NADPH oxidase: Potential relevance in diabetic nephropathy. J Am Soc Nephrol 14: S221-S226, 2003. (Pubitemid 36903929)
25. Lyras L, Cairns NJ, Jenner A, Jenner P, and Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 68: 2061-2069, 1997. (Pubitemid 27176143)
26. Mancardi GL, Perdelli F, Rivano C, Leonardi A, and Bugiani O. Thickening of the basement membrane of cortical capillaries in Alzheimer's disease. Acta Neuropathol 49: 79-83, 1980. (Pubitemid 10139968)
27. Marco S and Skaper SD. Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 401: 219-224, 2006. (Pubitemid 44250979)
28. Overgaard CE, Daugherty BL, Mitchell LA, and Koval M. Claudins: control of barrier function and regulation in response to oxidant stress. Antioxid Redox Signal 15: 1179-1193, 2011.
29. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, and Iadecola C. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 25: 1769-1177, 2005.
30. Perlmutter LS and Chui HC. Microangiopathy, the vascular basement membrane and Alzheimer's disease: A review. Brain Res Bull 24: 677-686, 1990. (Pubitemid 20183782)
31. Rensink AA, de Waal RM, Kremer B, and Verbeek MM. Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 43: 207-223, 2003. (Pubitemid 37315654)
32. Richard E, Carrano A, Hoozemans JJ, van Horssen J, van Haastert ES, Eurelings LS, de Vries HE, Thal DR, Eikelenboom P, van Gool WA, and Rozemuller AJ. Characteristics of dyshoric capillary cerebral amyloid angiopathy. J Neuropathol Exp Neurol 69: 1158-1167, 2010.
33. Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, and Masters CL. A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 48: 674-691, 1989. (Pubitemid 19257817)
34. Schreibelt G, Kooij G, Reijerkerk A, van Doorn R, Gringhuis SI, van der Pol S, Weksler BB, Romero IA, Couraud PO, Piontek J, Blasig IE, Dijkstra CD, Ronken E, and de Vries HE. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J 21: 3666-3676, 2007. (Pubitemid 350075154)
35. Sorce S and Krause KH. NOX enzymes in the central nervous system: From signaling to disease. Antioxid Redox Signal 11: 2481-2504, 2009.
36. Tai LM, Holloway KA, Male DK, Loughlin AJ, and Romero IA. Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell MolMed 14: 1101-1112, 2010.
37. Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del Tredici K, and Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61: 282-293, 2002. (Pubitemid 34212603)
38. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 552: 335-344, 2003. (Pubitemid 37321833)
39. van Horssen J, de Jong D, de Waal RM, Maass C, Otte-Holler I, Kremer B, Verbeek MM, and Wesseling P. Cerebral amyloid angiopathy with severe secondary vascular pathology: A histopathological study. Dement Geriatr Cogn Disord 20: 321-330, 2005. (Pubitemid 41442859)
40. van Wetering S, van Buul JD, Quik S, Mul FP, Anthony EC, ten Klooster JP, Collard JG, and Hordijk PL. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci 115: 1837-1846, 2002. (Pubitemid 34567245)
41. Wang J, Xiong S, Xie C, Markesbery WR, and Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93: 953-962, 2005. (Pubitemid 40695754)
42. Wang X, Su B, Perry G, Smith MA, and Zhu X. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med 43: 1569-1573, 2007. (Pubitemid 350122990)
43. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, and Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-694, 2001.
44. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, and Couraud PO. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19: 1872-1874, 2005. (Pubitemid 41598779)
45. Wisniewski HM, Vorbrodt AW, and Wegiel J. Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann NY Acad Sci 826: 161-172, 1997. (Pubitemid 27478038)
46. Yamashita K, Miyakawa T, and Katsuragi S. Vascular changes in the brains with Alzheimer's disease. Jpn J Psychiatry Neurol 45: 79-84, 1991.
47. Zhou J, Zhang S, Zhao X, and Wei T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res 45: 157-165, 2008.
48. Zhu X, Perry G, Moreira PI, Aliev G, Cash AD, Hirai K, and Smith MA. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 9: 147-153, 2006. (Pubitemid 44078642)
49. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, and Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28: 977-986, 2007. (Pubitemid 46635913)
50. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201, 2008.